Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286040/
https://www.ncbi.nlm.nih.gov/pubmed/32434813
http://dx.doi.org/10.1136/annrheumdis-2019-216118corr1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286040/
https://www.ncbi.nlm.nih.gov/pubmed/32434813
http://dx.doi.org/10.1136/annrheumdis-2019-216118corr1

Ejemplares similares